Article Text

other Versions

PDF
Concise report
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
  1. Carrie L Wagner1,
  2. Sudha Visvanathan2,
  3. Michael Elashoff3,
  4. Iain B McInnes4,
  5. Philip J Mease5,
  6. Gerald G Krueger6,
  7. Frederick T Murphy7,
  8. Kim Papp8,
  9. Juan J Gomez-Reino9,
  10. Michael Mack10,
  11. Anna Beutler11,
  12. Dafna Gladman11,
  13. Arthur Kavanaugh12
  1. 1Department of Immunology, Janssen Research & Development LLC, Spring House, Pennsylvania, USA
  2. 2Boehringer-Ingelheim, Ridgefield, Connecticut, USA
  3. 3Elashoff Consulting LLC, Redwood City, California, USA
  4. 4Division of Immunology, Infection, and Inflammation, University of Glasgow, Glasgow, Scotland, UK
  5. 5Swedish Medical Center and Seattle Rheumatology Associates, Seattle, Washington, USA
  6. 6Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
  7. 7Altoona Arthritis and Osteoporosis Center, Altoona, Pennsylvania, USA
  8. 8Probity Medical Research, Waterloo, Ontario, Canada
  9. 9Department of Medicine, University of Santiago de Compostela, and Rheumatology, Hospital Clinico Universitario, Santiago de Compostela, Spain
  10. 10Department of Biostatistics, Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
  11. 11University of Toronto, Toronto Western Research Institute, and Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
  12. 12Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego Rheumatology, La Jolla, California, USA
  1. Correspondence to Dr Carrie Wagner, Department of Immunology, Janssen Research & Development, LLC, 1400 McKean Road, PO Box 776, Spring House, PA 19477, USA; cwagner{at}its.jnj.com

Abstract

Objective To determine serum biomarker associations with clinical response to golimumab treatment in patients with psoriatic arthritis (PsA).

Methods GO–REVEAL was a randomised, placebo-controlled study of golimumab in patients with active PsA. Samples were collected from 100 patients at baseline, week 4 and week 14, and analysed for serum-based biomarkers and protein profiling (total 92 markers); data were correlated with clinical measures at week 14.

Results Serum levels of a subset of proteins (apolipoprotein C III, ENRAGE, IL-16, myeloperoxidase, vascular endothelial growth factor, pyridinoline, matrix metalloproteinase 3, C-reactive protein (CRP), carcinoembryonic antigen, intercellular adhesion molecule 1 and macrophage inflammatory protein 1α) at baseline or week 4 were strongly associated with American College of Rheumatology 20% improvement (ACR20) response and/or disease activity score in 28 joints (DAS28) at week 14. A smaller subset of proteins was significantly associated with a 75% improvement in the psoriasis area and severity index score (PASI75) at week 14, (adiponectin, apolipoprotein CIII, serum glutamic oxaloacetic transaminase, and tumour necrosis factor α). Subsets of proteins were identified as potentially predictive of clinical response for each of the clinical measures, and the power of these biomarker panels to predict clinical response to golimumab treatment was stronger than for CRP alone.

Conclusions This analysis provides insight into several panels of markers that may have utility in identifying PsA patients likely to have ACR20, DAS28, or PASI75 responses following golimumab treatment.

  • Psoriatic Arthritis
  • Anti-TNF
  • TNF-alpha

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.